M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pegasys® in Patients With Myeloproliferative Diseases

Phase 2

Completed

Conditions: Myeloproliferative Disorders

Interventions: Drug: IFN-alpha2a

First Posted Date: 2007-03-26

Last Posted Date: 2024-12-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 83

Registration Number: NCT00452023

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes

Phase 2

Completed

Conditions: Leukemia, Myeloid
Myelodysplastic Syndromes

Interventions: Drug: Gleevec
Drug: Ara-C

First Posted Date: 2007-03-26

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00451997

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Fatigue Experience in Cancer Patients

Completed

Conditions: Advanced Cancer

Interventions: Behavioral: Questionnaire
Behavioral: Interview

First Posted Date: 2007-03-22

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 73

Registration Number: NCT00450541

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

Phase 2

Completed

Conditions: Systemic Mastocytosis

Interventions: Drug: RAD001 (Everolimus)

First Posted Date: 2007-03-21

Last Posted Date: 2023-10-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00449748

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Six-Minute Walk Test in Patients at High Risk for Complications From Lung Resection

Conditions: Lung Cancer

Interventions: Other: Six-Minute Walk Test
Other: Exercise stress test

First Posted Date: 2007-03-21

Last Posted Date: 2019-05-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 101

Registration Number: NCT00450125

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Rituximab
Drug: Bevacizumab

First Posted Date: 2007-03-15

Last Posted Date: 2015-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 64

Registration Number: NCT00448019

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia

Phase 2

Withdrawn

Conditions: Leukemia

Interventions: Drug: Busulfan
Drug: Cyclophosphamide
Drug: G-CSF
Drug: GM-CSF

First Posted Date: 2007-03-12

Last Posted Date: 2015-08-25

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00446173

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Effectiveness of Protected Environment Rooms for AML and MDS

Terminated

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome

First Posted Date: 2007-03-05

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00443300

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Hodgkin Lymphoma

Interventions: Drug: Bortezomib
Drug: Carboplatin
Drug: Etoposide
Drug: Ifosfamide
Drug: Mesna

First Posted Date: 2007-02-23

Last Posted Date: 2012-07-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT00439361

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Oral Margin Spectroscopy Detection Using Optical Spectroscopy

Completed

Conditions: Oral Tumors

Interventions: Device: FastEEM4 System
Device: Multispectral Digital Microscope

First Posted Date: 2007-02-23

Last Posted Date: 2017-10-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 58

Registration Number: NCT00439205

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy